AZGP1 and prostate cancer: To evaluate whether AZGP1 could affect microvessel density in AR + clinically localized human prostate cancer, we used the CellDIVE platform to perform multiplex immunohistochemistry analyses on a human prostate cancer tissue microarray (TMA) containing 215 cases.